Adjunctive atorvastatin in moderate-to-severe thyroid eye disease (SEMAR-TED: Structural, Biomarker Expression and Muscle endpoints of Atorvastatin): study protocol for a randomised, open-label, assessor-masked controlled trial
The SEMAR-TED study protocol outlines a randomized, open-label, assessor-masked controlled trial in Indonesia investigating whether adding oral atorvastatin to intravenous glucocorticoids improves orbital muscle diameter and molecular biomarkers in adults with active, moderate-to-severe thyroid eye disease, regardless of baseline cholesterol levels.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Thyroid eye disease is a condition where the body's immune system mistakenly attacks the tissues behind the eyes. Instead of just causing inflammation, this attack triggers the muscles that move the eyeball and the fatty tissue surrounding them to swell and grow. This swelling pushes the eyes forward, causing them to bulge, and can make it difficult to close the eyelids or see clearly. For many people, the disease is disfiguring and disabling, and in severe cases, it can threaten vision. The standard medical treatment involves giving patients high doses of steroid medicine through a vein to calm the immune system down. While this works for many, it fails to stop the disease in a significant number of patients, and the current options for additional treatment are either too expensive or simply unavailable in many parts of the world.
Researchers have long wondered if a common, inexpensive class of drugs known as statins, usually prescribed to lower cholesterol, could help treat this condition. Statins do more than just clean up blood fats; they also have the ability to calm inflammation and stop certain cells from growing too fast. A previous study in Europe suggested that adding a statin to the standard steroid treatment helped some patients, but that study only included people who already had high cholesterol. This left a big question unanswered: would the drug help people with normal cholesterol levels, and does it actually shrink the swollen eye muscles, or does it just make patients feel better? To find the answers, a team of researchers in Indonesia designed a new clinical trial called SEMAR-TED to test whether adding a statin to the standard care truly changes the physical structure of the eye.
The study will take place at a major hospital in Yogyakarta, Indonesia, where the researchers plan to recruit up to sixty-four adults suffering from active, moderate-to-severe thyroid eye disease. These patients will be randomly divided into two groups. Both groups will receive the standard treatment: a series of intravenous steroid infusions given once a week for twelve weeks. The first group will receive only the steroids, while the second group will receive the same steroids plus a daily pill of atorvastatin, a common statin, for twenty-four weeks. Unlike the previous European study, the researchers will not check the patients' cholesterol levels before letting them join. They want to see if the drug works for everyone, regardless of their blood fat levels. The doctors giving the treatment will know which pill each patient is taking, but the team measuring the results will not, ensuring that the final assessment remains unbiased.
The most important measure of success in this trial is not how the patients feel, but what the scans show. The researchers will use specialized computerized tomography scans to take precise pictures of the muscles behind the eyes. They will measure the thickness of four specific muscles that control eye movement. The main goal is to see if the group taking the statin has a greater reduction in muscle size after twenty-four weeks compared to the group taking steroids alone. They will also look at the volume of fatty tissue in the eye socket and measure specific genetic signals in the blood and in small tissue samples taken during surgery. These tissue samples will only be collected from patients who are already scheduled for surgery to relieve pressure on the eye, so the research will not add any extra risk or change the timing of their operations.
The results of this trial are not yet available, as the paper describes the plan and design of the study rather than the final data. However, the design itself reveals a significant shift in how scientists are approaching this disease. By making the physical size of the eye muscles the primary goal, rather than just a list of symptoms, the researchers are looking for hard, measurable proof that the drug changes the anatomy of the eye. They are also testing whether the drug works through the same mechanism that lowers cholesterol or through a different pathway that calms inflammation directly. If the statin group shows smaller muscles and lower levels of inflammatory signals, it would suggest that this cheap, widely available drug could become a standard part of treatment for patients who cannot afford newer, expensive therapies.
This study is a crucial step because it is the first of its kind to be conducted in Indonesia and the first to include patients with normal cholesterol levels. It also marks the first time a randomized trial in this field has used detailed imaging as its main measure of success. While the researchers acknowledge that a single study at one hospital is not enough to change global medical practice immediately, the findings will provide essential data. If the statin proves effective, it could offer a lifeline to patients in settings where the most advanced treatments are out of reach. If it does not work, the trial will still provide valuable information about what the drug does and does not do to the eye, helping to guide future research toward more effective solutions for a condition that currently leaves many without hope.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.